Illumina Inc. (ILMN)

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Citi lowered the firm's price target on Illumina to $85 from $90 and keeps a Neutral rating on the shares as part of a Q1 preview for the life science tools and diagnostics group. The firm believes ta...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.

The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing ...

Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citin...

Keith Meister's hedge fund Corvex Management has a 2.5% stake in the gene-sequencing machine maker.

ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value inv...